New Delhi, Mar 14 (PTI) Zydus Lifesciences Ltd on Monday said it has received the final approval from the US health regulator to market its generic version of colestipol hydrochloride tablets, which is used to lower cholesterol.

The approval by the US Food and Drug Administration is for colestipol hydrochloride of 1 mg strength, the company said in a regulatory filing.

Also Read | Telegram Introduces New Download Manager, Live Streaming With Other Apps.

Colestipol hydrochloride tablets are indicated as adjunctive therapy to diet for the reduction of elevated serum total and LDL-C (low-density lipoprotein, known as bad cholesterol) in patients with primary hypercholesterolemia (elevated LDL-C) who do not respond adequately to diet, it added.

"Zydus' ANDA is only the second generic application approved by USFDA for this product," it said.

Also Read | Samsung Likely To Unveil New Galaxy A Series Smartphones on March 17, 2022: Report.

The drug will be manufactured at the group's formulation manufacturing facility at SEZ, Ahmedabad, the company added. HRS hrs

(The above story is verified and authored by Press Trust of India (PTI) staff. PTI, India’s premier news agency, employs more than 400 journalists and 500 stringers to cover almost every district and small town in India.. The views appearing in the above post do not reflect the opinions of LatestLY)